Tubulin-Binding Compounds for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimitotic drugs for treating cancers, such as microtubule-targeting agents, face challenges including dose-limiting toxicities, resistance due to efflux pumps and tubulin mutations, and limited solubility, necessitating the development of novel tubulin-targeting compounds with improved properties.
Innovation Solution
Development of novel compounds that bind to tubulin, inhibit microtubule polymerization, arrest cells in mitosis, and induce apoptosis, represented by specific chemical formulas (e.g., Formula I and Formula II), which are selective modulators of microtubules and can be used to treat hyperproliferative disorders like cancers and myelodysplastic syndromes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If microtubule-targeting agents are used to treat cancer, then cell proliferation is inhibited, but dose-limiting toxicities occur
Solution Approach 1:
The patent modifies the chemical structure of tubulin-binding compounds by changing parameters such as the core structure (e.g., indole, pyridine rings), substituent groups (e.g., halogen, alkyl, aryl groups), and molecular weight to develop analogs with improved therapeutic index while maintaining anticancer activity
Solution Approach 2:
The patent creates composite chemical structures combining multiple functional groups and ring systems (e.g., fused ring systems with nitrogen-containing heterocycles) to achieve both high efficacy and reduced toxicity through optimized molecular properties
2Reliability
If microtubule-targeting agents are used to treat cancer, then cell division is arrested, but resistance develops due to efflux pumps and tubulin mutations
Solution Approach 1:
The patent develops a series of chemical analogs with varying molecular weights, hydrophobicity, and structural features to overcome resistance mechanisms by finding compounds that are not recognized by efflux pumps or do not bind to mutated tubulin isoforms
Solution Approach 2:
The patent designs compounds with broad-spectrum activity against multiple cancer types and resistance profiles by incorporating versatile core structures that can interact with various tubulin isoforms and binding sites
3Reliability
If microtubule-targeting agents are used to treat cancer, then tumor growth is inhibited, but solubility is limited
Solution Approach 1:
The patent modifies physical-chemical parameters of the compounds including adding polar groups, modifying ring structures, and adjusting molecular weight to improve aqueous solubility while preserving the ability to bind tubulin and inhibit microtubule polymerization
Solution Approach 2:
The patent employs solubilizing groups and prodrug strategies as intermediaries to enhance the solubility of hydrophobic tubulin-binding compounds without affecting their biological activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit cell proliferation, induce mitotic arrest, and trigger apoptosis in cancer cells, offering potential as more soluble and effective alternatives to existing microtubule-targeting agents, including those resistant to paclitaxel.
Implementation Method 1
These compounds effectively inhibit cell proliferation, induce mitotic arrest, and trigger apoptosis in cancer cells
Data Source
AI summary
This disclosure relates to methods of treating cancer (e.g., melanoma) with(MI-181).